EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 119 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Mom Says Family Was Kicked Out Of Movie Theater Because Her... April 19, 2019 The Doctor Will See You Now…On the Screen July 2, 2020 FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection October 2, 2025 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 Load more HOT NEWS How does processed and red meat cause cancer and how much... How My Cancer Diagnosis at Age 17 Changed My Perspective on... Severe Side Effects of Cancer Treatment Are More Common in Women... Development of Secondary T-Cell Cancers After the Use of CAR T-Cells...
